🚨EXACERBATION WATCH — When to Call, When to ED
A COPD exacerbation is an acute worsening of symptoms beyond day-to-day variation — increased dyspnea, increased sputum, sputum color change, increased cough. Most morbidity and mortality in COPD clusters around exacerbations. Early recognition + early treatment shortens duration and reduces hospitalization. Have a written Action Plan + rescue meds at home.
🎯Three Phases · One Force Field
Every square belongs to one of three phases of mastery. Inside each square's detail panel, the four sections — Concepts · Skills · Actions · Plan — are the building blocks of these phases.
📘 Learn It Tier 1 · Aware
Identity earned: Self-Advocate. The "know" — what COPD is (chronic airflow limitation; emphysema + chronic bronchitis), how GOLD staging works (1–4 by FEV1; A/B/E groups by symptoms + exacerbations), the smoking-cessation imperative, the alpha-1 antitrypsin screen, and the honest framing that COPD is progressive but the rate of progression is highly modifiable.
🛠 Live It Tier 2 · Active
Identity earned: Care-Team Member. The "do" — daily skills (LAMA/LABA/ICS adherence + correct inhaler technique with spacer, smoking cessation, pulmonary rehab enrollment, LTOT if hypoxemic, annual vaccinations, exacerbation Action Plan, pulse ox at home) and this-week actions that turn skills into habits — including building the family Ambassador partnership.
📣 Share It Tier 3 · Certified
Identity earned: Ambassador. The "carry forward" — handle COPD identity honestly (without stigma), mentor a newly-diagnosed person via COPD Foundation / ALA, advocate for spirometry + pulmonary-rehab + LTOT access in your community, normalize advance care planning, and close the underdiagnosis gap (especially in women, AA, Indigenous, rural).
🛡️Your Force Field — 16 Squares
Click any square to open its detail panel. Each square is a tile in your shield. Keep clicking, learning, and acting — your Force Field gets stronger every step.
What Is COPD?
A progressive disease of chronic airflow limitation from inflammation + structural lung changes — emphysema (destruction of alveoli) + chronic bronchitis (mucus + airway inflammation). Most cases are smoking-related; alpha-1 antitrypsin deficiency + occupational dust + biomass smoke + air pollution also cause it. ~16M diagnosed + ~12M undiagnosed US adults. Smoking cessation is the #1 disease-modifying intervention.
Primer360 Human Anatomy
Airway, Alveoli, Mucus, Diaphragm
The lower airways (bronchi → bronchioles) carry air to alveoli — tiny sacs where O₂ enters blood + CO₂ exits. In COPD: chronic bronchitis inflames airways + increases mucus; emphysema destroys alveolar walls (loss of elastic recoil, gas-trapping, hyperinflation). The diaphragm flattens from hyperinflation, working harder for less air. Alpha-1 antitrypsin normally protects alveoli from elastase; deficiency = early-onset COPD even without smoking.
AnatomyWho Gets It? — Causes + Types
Smoking is the #1 cause (~80–85% of cases) — both active and substantial passive exposure. Alpha-1 antitrypsin deficiency (1 in ~3,000 — under-diagnosed; one-time blood test). Occupational dust + fumes (coal, silica, cadmium, agricultural, welding). Indoor biomass smoke (wood / coal cooking + heating — major in global cohorts). Outdoor air pollution. Childhood respiratory infections may lower peak lung function. Asthma-COPD overlap (ACO) — common; often biologic-responsive. Women are now ~60% of US COPD deaths; underdiagnosis historical.
PrimerThe Numbers — GOLD 1–4, A/B/E, FEV1, CAT
~16M diagnosed US adults; ~12M undiagnosed. 4th leading cause of US death. Spirometry post-bronchodilator FEV1/FVC <0.7 = obstruction. GOLD 1–4 by FEV1 % predicted: GOLD 1 ≥80% · GOLD 2 50–79% · GOLD 3 30–49% · GOLD 4 <30%. GOLD 2024 ABE groups by symptoms (mMRC or CAT) + exacerbations: A low symptoms/few exacerbations · B high symptoms/few exacerbations · E any with ≥2 moderate or ≥1 severe (hospitalized) exacerbation/year. CAT (COPD Assessment Test) ≥10 = symptomatic. SpO₂ at rest + ambulation. 6-min walk distance.
PrimerRecognize Symptoms + Triggers
Symptoms: chronic dyspnea (often gradual onset, exertional first then at rest), chronic cough, sputum production, wheeze, recurrent respiratory infections, fatigue, weight loss in advanced disease. Triggers of exacerbations: viral URIs (#1; flu/COVID/RSV — vaccinate), bacterial infections, air pollution / wildfire smoke, environmental tobacco smoke, indoor pollutants (gas-stove combustion, candles, cleaning chemicals), cold/dry air, sometimes unclear. Spirometry is the diagnostic gold standard — under-utilized; many patients first diagnosed during an exacerbation.
Learn ItDiagnostic Workup + Wellness
Post-bronchodilator spirometry (FEV1/FVC <0.7) is required for diagnosis. CAT + mMRC for symptom burden. Exacerbation history last 12 months. Alpha-1 antitrypsin level — at least once in every COPD patient (under-diagnosed; reasonable in younger patients, early-onset, family history). Chest CT if hemoptysis, lung-cancer screening (eligible smokers/former smokers), or atypical features. Pulse oximetry + ABG if hypoxemia suspected. Echo if cor pulmonale suspected. BMI + sarcopenia assessment. Vaccinations: flu (annual), COVID (annual), RSV (60+), pneumococcal (PCV20 or PCV15+PPSV23), Tdap, shingles (50+). Bone density if chronic steroid use (cross-ref Osteoporosis).
Learn ItKnow My Numbers
FEV1 % predicted (GOLD 1–4) · FEV1/FVC ratio <0.7 = obstruction · CAT score ≥10 = symptomatic · mMRC dyspnea grade · SpO₂ at rest + ambulation (<88% sustained = LTOT criterion) · 6-min walk distance · BMI (cachexia = poor prognosis) · exacerbations / year (≥2 moderate or ≥1 severe = high-risk Group E) · blood eosinophils (helps decide ICS use; ≥300/μL favors ICS) · alpha-1 antitrypsin level (at least once) · vaccinations current · smoking status + pack-years. Bring a one-page numbers card.
Learn ItLifestyle Force Field — Cessation + Rehab + Vaccines
Smoking cessation is the #1 disease-modifying intervention — slows FEV1 decline, reduces exacerbations, reduces mortality, improves QoL. Quitline 1-800-QUIT-NOW + behavioral + pharmacologic (varenicline, NRT, bupropion). Pulmonary rehabilitation — 6–12 week multi-disciplinary program (exercise + education + nutrition + psychosocial) — improves mortality + QoL + exacerbation rate; under-prescribed. Annual vaccinations (viral URI = #1 exacerbation trigger). Air-quality awareness. Nutrition (protein adequacy; treat cachexia). Exercise daily (continue rehab gains). Indoor air (avoid smoke / candles / poor ventilation). Weight management (both obesity + cachexia worsen COPD).
Learn ItMedications + LTOT
LAMA (tiotropium, umeclidinium, glycopyrrolate, aclidinium) — first-line for symptomatic COPD. LABA (formoterol, salmeterol, indacaterol, vilanterol, olodaterol) — pair with LAMA for step-up. LAMA-LABA combos (Stiolto, Anoro, Bevespi, Duaklir). Triple therapy ICS-LABA-LAMA (Trelegy, Breztri) — for Group E or asthma-COPD overlap or eos ≥300/μL. ICS as monotherapy NOT recommended in COPD. Roflumilast (PDE4 inhibitor) for chronic bronchitis + frequent exacerbations. Azithromycin macrolide for frequent exacerbators (chronic low-dose). Dupilumab recently FDA-approved for COPD with eosinophilic phenotype (2024). Long-term oxygen therapy (LTOT) ≥15 hr/day for resting hypoxemia (SpO₂ <88% / PaO₂ <55) — prolongs survival. Inhaler technique + spacer with MDI critical.
Live ItCare Team Members
PCP (mild-moderate COPD lead) · Pulmonology (moderate-severe, frequent exacerbations, LTOT, alpha-1, advanced therapies) · Respiratory Therapist (RT) (inhaler technique, LTOT setup, NIV) · Pulmonary Rehab Program · Pharmacist (inhaler technique + adherence + copay) · Smoking-cessation counselor / Quitline 1-800-QUIT-NOW · Cardiology (CV is #1 cause of death in COPD) · Sleep Medicine (OSA-COPD overlap "overlap syndrome") · Behavioral Health (depression + anxiety ~40% prevalence; 988) · Dietitian (cachexia + sarcopenia + weight management) · Palliative Care (symptom + advance-care-planning support; not just hospice) · Thoracic Surgery / Interventional Pulm (lung volume reduction, transplant evaluation) · COPD Foundation peer + ALA support · Family Ambassador.
Live ItTelemedicine & Tech
Pulse oximeter at home ($20) — non-negotiable; track resting + ambulatory SpO₂. Telehealth well-suited for follow-up + exacerbation management + pulmonary rehab (post-program telehealth maintenance). Smart inhalers (Propeller, Hailie) track adherence + technique. Air-quality apps (AirNow, IQAir) for exposure avoidance. Spirometry-at-home (Spirohome, NuvoAir — emerging consumer). Portable oxygen concentrators (POCs) for LTOT mobility. Activity trackers with step count + heart rate. Telerehab programs are valid alternative to in-person pulmonary rehab where access is limited.
TechInsurance, Treatment Cost & Help
Generic LAMA + LAMA-LABA + ICS-LABA-LAMA are increasingly affordable (most $30–100/month with insurance; tiotropium Respimat still brand). LTOT covered by Medicare Part B with appropriate ABG / SpO₂ documentation. Pulmonary rehab covered by Medicare Part B (under-prescribed; advocate). Alpha-1 augmentation therapy (weekly IV) for confirmed deficient phenotype — very expensive; manufacturer copay programs available. Lung transplant for end-stage. ALA Lung HelpLine 1-800-LUNGUSA + COPD Foundation 1-866-731-COPD for navigation. NeedyMeds + RxAssist. VA covers COPD for veterans with service-connected exposure (Agent Orange, burn pits per PACT Act).
Live ItEquity, Access & Cultural Competence
Women are now ~60% of US COPD deaths — historically underdiagnosed because COPD was framed as "old white man's disease"; symptoms in women often attributed to anxiety / aging. AA Americans: higher COPD mortality + lower spirometry access + lower pulmonary-rehab referral. Indigenous + rural: spirometry access gaps; LTOT logistics harder. Lower-SES: occupational + indoor biomass + tobacco exposure stacked. LGBTQ+: care-access disparities. Veterans: Agent Orange + burn-pit exposure (PACT Act 2022 — much expanded eligibility); document service history. Alpha-1 antitrypsin deficiency is underdiagnosed across all groups — test at least once in every COPD patient. Smoking-stigma: barrier to seeking care; non-smokers also get COPD (~15% of cases). Don't be preachy — be specific.
Share ItTalk to Kids, Partner, Family, Employer
Kids (especially adult children): "Mom/Dad has COPD — chronic lung disease that limits how much air the lungs can move. Smoking is the #1 cause for most patients; alpha-1 antitrypsin deficiency runs in families. Help with the inhaler routine, pulmonary rehab, and LTOT if needed. The trajectory is highly modifiable." Partner: inhaler-technique coach + pulmonary-rehab partner + LTOT logistics + exacerbation-watch + advance-care-planning team. Family history of alpha-1 deficiency — first-degree relatives should be tested. Employer / HR: ADA covers COPD; reasonable accommodations (air quality, work-from-home, biologic-infusion / LTOT scheduling); FMLA for exacerbations + pulmonary rehab + hospitalization. Veterans: Agent Orange / burn-pit PACT Act eligibility.
Share ItMentor & Share Insights
COPD Foundation peer-mentor + COPD360social community + COPD360coach. ALA Better Breathers Clubs (community support groups). World COPD Day third Wednesday in November. National COPD Awareness Month November. The newly-diagnosed person who hears 'I'm GOLD 3, I quit smoking 8 years ago, I did pulm rehab, I'm on triple therapy, my CAT was 24, now it's 12, I walk 2 miles a day' gets a different orientation than statistics. Honest framing > pep talk. The Ambassador role for spirometry-access advocacy + pulm-rehab-referral advocacy + alpha-1 screening is real public-health work. The Ambassador role for advance care planning normalization in severe COPD is real public-health work.
Share ItJoin the ROI Study (PHIT)
PHIT — Population Health Impact Tracking. Pairs COPD-specific outcome tracking with cost data — FEV1 trend, CAT trend, exacerbations/year, pulmonary-rehab uptake, LTOT criteria-met rates, alpha-1 screening rates, smoking-cessation success, vaccinations, ED visits, hospitalizations, equity (women / AA / Indigenous / rural specialty access), badge progress, self-reported QoL. Aggregate & anonymous. Cross-references SPIROMICS, COPDGene, COPD Foundation Patient-Powered Research Network.
Study🩺 Hand-off to my COPD Team
Print and bring to your next visit. This page tells your team what you have prepared for, what you want to focus on, and how you would like to participate as an active member of your own care team.
- I am a Prepared Patient in training for COPD. I have reviewed all 16 squares of this Force Field Fact Sheet.
- I have started building my Health Passport, my FEV1 + CAT + mMRC log, my exacerbation log, my pulse-ox at-home log, my vaccination record, my inhaler-technique check date, my smoking-status / cessation plan, my alpha-1 antitrypsin screen status, my pulmonary-rehab participation, my LTOT status if applicable, and my written Exacerbation Action Plan to bring to every visit.
- I want to teach back what I have learned and have you correct anything I have misunderstood — especially around my GOLD stage + ABE group, my inhaler regimen with spacer + technique, the absolute rule of never stopping LTOT abruptly, when to call vs go to ED (severe dyspnea / confusion / cyanosis / SpO₂ <88% sustained), my alpha-1 status, my advance-care-planning preferences, and whether I'm a biologic candidate (dupilumab for eosinophilic COPD).
What helps my visit
Two minutes for me to teach back. One question I prepared. My CAT score + exacerbation count + pulse-ox log + inhaler-technique review. Confirm my GOLD stage + ABE group, alpha-1 status, pulmonary-rehab participation, and biologic eligibility on the chart. Don't accept ≥2 exacerbations/year as normal.
What I am working on
Smoking cessation (Quitline 1-800-QUIT-NOW) · LAMA-LABA + ICS if Group E or eos ≥300 · correct inhaler technique with spacer · annual vaccines (flu, COVID, RSV, pneumococcal) · pulmonary rehab enrollment · pulse-ox at-home tracking · LTOT if hypoxemic · exacerbation Action Plan · alpha-1 testing · CV-risk management (CV is #1 killer in COPD) · advance care planning.
How I want to participate
Shared decisions. Honest conversation about triple therapy, biologic candidacy if eos ≥300, LTOT criteria, lung volume reduction / transplant if very severe. AHRQ SHARE Approach. Don't normalize ≥2 exacerbations/year. Don't skip the alpha-1 screen. Don't delay pulmonary rehab. Normalize advance care planning early.
🔬 Help Prove This Works — Join the FFH ROI & PHIT Study
The Prepared Patient program is being studied to see whether better preparation actually improves outcomes — better FEV1 + CAT trend, fewer exacerbations, higher pulmonary-rehab uptake, more LTOT-criteria-met patients on therapy, higher alpha-1 screening rates, higher smoking-cessation success, more vaccinations, fewer ED visits + hospitalizations, more equitable specialty-care access for women / AA / Indigenous / rural patients — for COPD patients and families. Your participation is voluntary, your data is aggregated and anonymized, and you can withdraw at any time.
➕ Add-On Force Field Card · COPD Skill Mastery
If your care plan adds a specific skill or device, bolt on a 5-step Add-On Card. For COPD common bolt-ons include: inhaler-technique-with-spacer routine, smoking-cessation routine (Quitline + pharmacologic + behavioral), pulmonary rehab enrollment + post-rehab maintenance, LTOT setup + portable concentrator logistics, pulse-ox at-home tracking, written Exacerbation Action Plan with rescue albuterol + oral steroid + antibiotic + when-to-call, alpha-1 antitrypsin testing (one-time blood test), CV-risk audit (BP, statin, A1c — CV is #1 killer in COPD), nutrition adequacy (protein + cachexia management), advance care planning conversation, lung-cancer screening (LDCT eligibility), Veterans PACT Act eligibility for Agent Orange / burn-pit exposure, family Ambassador exacerbation-watch + LTOT-logistics drill.
Introduce
What it is, why it matters, what it does
Coach
Watch a demo + walk-through
Practice
Do it with a coach watching
Train
Use it daily with a check-in
Test
Demonstrate competence + earn badge
Ready to go deeper?
The Prepared Patient · COPD course turns this fact sheet into a guided journey: pre/post knowledge checks, the chronic-airflow-limitation mental model, GOLD staging + ABE groups, smoking cessation as the #1 disease-modifying intervention, the pulmonary-rehab evidence base, LTOT criteria + mortality benefit, alpha-1 antitrypsin screening, the LAMA / LABA / ICS hierarchy (and when biologics enter for eosinophilic COPD), the exacerbation cycle + written Action Plan, the CV-is-#1-killer reality, advance care planning normalization, the underdiagnosis-in-women + AA + Indigenous + rural story, Veterans PACT Act, and your printable Health Passport. Earn Aware → Active → Certified.